Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 October 2021, including: a slow start for Biogen, Inc.’s Aduhelm; Johnson & Johnson looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bioUCB S.A. faces bimekizumab delays; and progress and setbacks in gene therapy.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Biogen’s Q3 Aduhelm Sales Even Worse Than Expected" - Scrip, 20 Oct, 2021.)
 

(Also see "Bluebird Spinoff 2seventy Bio Gets Its Own Wings" - Scrip, 19 Oct, 2021.)

(Also see "UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug" - Scrip, 18 Oct, 2021.)

(Also see "The Next Big Thing In Gene Therapy Might Not Be Gene Therapy" - Scrip, 15 Oct, 2021.)

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel